Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate.

Zika virus (ZIKV) is an important re-emerging flavivirus that presents a significant threat to human health worldwide. Despite its importance, no vaccines are approved for use in humans. Insect-specific flaviviruses (ISFVs) have recently garnered attention as an antigen presentation platform for vaccine development and diagnostic applications. Here, we further explore the safety, immunogenicity, and efficacy of a chimeric ISFV-Zika vaccine candidate, designated Aripo-Zika (ARPV/ZIKV). Our results show a near-linear relationship between increased dose and immunogenicity, with 1011 genome copies (i.e., 108 focus forming units) being the minimum dose required for protection from ZIKV-induced morbidity and mortality in mice. Including boosters did not significantly increase the short-term efficacy of ARPV/ZIKV-vaccinated mice. We also show that weanling mice derived from ARPV/ZIKV-vaccinated dams were completely protected from ZIKV-induced morbidity and mortality upon challenge, suggesting efficient transfer of maternally-derived protective antibodies. Finally, in vitro coinfection studies of ZIKV with Aripo virus (ARPV) and ARPV/ZIKV in African green monkey kidney cells (i.e., Vero-76) showed that ARPV and ARPV/ZIKV remain incapable of replication in vertebrate cells, despite the presence of active ZIKV replication. Altogether, our data continue to support ISFV-based vaccines, and specifically the ARPV backbone is a safe, immunogenic and effective vaccine strategy for flaviviruses.

Novel murine models for studying Cache Valley virus pathogenesis and in utero transmission.

Cache Valley virus (CVV) is a prevalent emerging pathogen of significant importance to agricultural and human health in North America. Emergence in livestock can result in substantial agroeconomic losses resulting from the severe embryonic lethality associated with infection during pregnancy. Although CVV pathogenesis has been well described in ruminants, small animal models are still unavailable, which limits our ability to study its pathogenesis and perform preclinical testing of therapeutics. Herein, we explored CVV pathogenesis, tissue tropism, and disease outcomes in a variety of murine models, including immune -competent and -compromised animals. Our results show that development of CVV disease in mice is dependent on innate immune responses, and type I interferon signalling is essential for preventing infection in mice. IFN-αßR-/- mice infected with CVV present with significant disease and lethal infections, with minimal differences in age-dependent pathogenesis, suggesting this model is appropriate for pathogenesis-related, and short- and long-term therapeutic studies. We also developed a novel CVV in utero transmission model that showed high rates of transmission, spontaneous abortions, and congenital malformations during infection. CVV infection presents a wide tissue tropism, with significant amplification in liver, spleen, and placenta tissues. Immune-competent mice are generally resistant to infection, and only show disease in an age dependent manner. Given the high seropositivity rates in regions of North America, and the continuing geographic expansion of competent mosquito vectors, the risk of epidemic and epizootic emergence of CVV is high, and interventions are needed for this important pathogen.

Effects of methylmercury on mosquito oviposition behavior: Maladaptive response to non-toxic exposure.

Animals can modulate their own exposure to environmental contaminants through behavioral plasticity such as diet and habitat choice. However, it remains unclear if behavior also has cascading effects on contaminant exposure across multiple generations. In insects, oviposition site selection is an important behavior females can use to modify offspring contaminant exposure risk. In this study, we use the yellow fever mosquito, Aedes aegypti, to test how methylmercury (MeHg) affects oviposition site selection. We found that mosquito larval development rate and survival were negatively affected at MeHg concentrations ≥100 ppb. Adult females not exposed to MeHg as larvae avoided oviposition sites with high MeHg concentrations (>50 ppb), but MeHg exposure at the larval stage significantly affected this oviposition site selection. Specifically, females raised from larvae exposed to non-toxic MeHg levels (i.e., five-50 ppb) showed a significant increase in preference for oviposition sites contaminated with toxic MeHg concentrations (≥500 ppb), compared to unexposed controls. This maladaptive behavioral response could be because, when conditioned with non-toxic MeHg concentrations, MeHg-associated olfactory cues act as a "supernormal" stimulus during oviposition site selection. Importantly, however, this maladaptive behavioral response is eliminated in female mosquitoes raised from larvae exposed to toxic MeHg concentrations (i.e. 100 ppb), and these mosquitoes showed a significant increase in preference for MeHg uncontaminated oviposition sites, compared to unexposed controls. Thus, in mosquitoes, the magnitude of MeHg exposure in one generation can impact MeHg exposure in subsequent generations by altering oviposition site selection behavior. Our results have broad implications for our understanding of how contaminant-mediated behavioral modifications can feedback on contaminant exposure risk across multiple generations, and consequently how behavior can affect the evolutionary trajectory of organisms inhabiting a heterogeneously contaminated environment.